Tasmina Goraya

Tasmina is a partner in the firm's Patent team and is a core member of the firm's UK and International Life Sciences Group.

She works with our clients in the life sciences sector advising on contentious and non-contentious areas, including a broad range of regulatory and compliance issues relating to pharmaceuticals, medical devices, food supplements, human cells and tissue. Tasmina regularly advises on patent, regulatory and contract disputes, with a particular focus on arbitrations as well as the regulatory aspects of corporate transactions. Tasmina further assists clients with specialist agreements, such as clinical trials agreements.

显示完整简历隐藏完整简历

职业发展

Since 2019	Partner, Taylor Wessing
2017 - 2019	Senior Associate, Taylor Wessing
2016 - 2017	Associate, Taylor Wessing

2011 - 2016	Associate, Bird & Bird
2006 - 2011	Paralegal, Trainee Solicitor, Mills & Reeve
2003 - 2006	Postdoctoral Research Associate, Pharmacology, University of Cambridge

更多更少

教育

2013	Postgraduate Diploma, Intellectual Property Law and Practice, Oxford University
2011	Admitted as a solicitor, England & Wales
2009	Legal Practice Course, College of Law

2007	Diploma in Law, College of Law
2003	PhD, Pharmacology, thesis on 'The regulation of intracellular calcium release by parathyroid hormone', Cambridge University
1999	BSc, Toxicology & Pharmacology, The School of Pharmacy, University of London

更多更少

语言

English

专长

执业领域和服务团队专利与创新产品责任与产品安全

行业酒店与休闲医疗器械

Experience

Sale of S&IP business	Halyard Health on the sale of its surgical and infection prevention (S&IP) business to OMI.
Apotex's EUR74m sale of subsidiaries to Aurobindo	Apotex on the sale of six European subsidiaries in Belgium, Poland, the Netherlands, Czech Republic and Spain, to Aurobindo for EUR74 million. This highly complex transaction involved the share transfer of subsidiaries in multiple jurisdictions being co-ordinated and managed by our UK team. We simultaneously advised on a multitude of business separation, ongoing product supply agreements and IP licences for the European business to continue operating after being removed from the Apotex group.
Acting on a multi-million pound arbitration claim	A medical research organisation in a multi-million pound arbitration claim against a Japanese pharmaceutical company, seeking royalties due on the sales of a blockbuster drug resulting from an R&D collaboration between the parties.